Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead

Showing 15 posts of 244 posts found.

800px-who_flag_2

WHO warns regulators to consider all available evidence before approving remdesivir for COVID-19

October 26, 2020
Sales and Marketing COVID, COVID-19, Gilead, coronavirus

The World Health Organization’s Chief Scientist Soumya Swaminathan has warned that experts and regulators assessing the use of Gilead’s remdesivir …

News
fdaoutsideweb

FDA approves Gilead’s remdesivir for hospitalised COVID-19 patients

October 23, 2020
Medical Communications, Sales and Marketing COVID-19, FDA, Gilead, remdesivir

The FDA has approved Gilead’s antiviral therapy Veklury (remdesivir) for the treatment of hospitalised COVID-19 patients, making it the first …

News
gilead-sciences

Gilead’s Biktarvy proves non-inferior to standard care for HIV in Black and African American patients

October 22, 2020
Research and Development Biktarvy, Gilead, HIV, pharma

Gilead has revealed promising new Phase 3 data reinforcing the non-inferiority of Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg) compared to …

News
eu_member_flags

European Commission stands by €1bn remdesivir supply deal despite disappointing COVID-19 benefit

October 19, 2020
Manufacturing and Production, Sales and Marketing COVID-19, Europe, Gilead, remdesivir

As Europe continues to face down a rising second wave of COVID-19, the European Commission quickly moved to secure a …

News
shutterstock_2

Gilead to meet rising remdesivir demand in Europe with new supply deal

October 8, 2020
Manufacturing and Production COVID-19, Europe, Gilead

The European Commission (EC) has signed a new joint procurement agreement (JPA) with pharma firm Gilead to improve access to …

News
shutter

Japan approves Gilead and Eisai’s Jyseleca for rheumatoid arthritis

September 25, 2020
Medical Communications, Sales and Marketing Eisai, Gilead, Japan, Jyseleca

Gilead and Eisai have secured approval for their oral JAK1 preferential inhibitor Jyseleca (filgotinib) from the Japanese Ministry of Health, …

News
49449461223_6e279556d2_b

Gilead agrees to pay $97 million to settle Medicare kickbacks case

September 24, 2020
Business Services Gilead, Medicare, drugs, kickbacks

Gilead has agreed to pay $97 million to resolve claims from the US Government that it used an independent charity …

News
shutterstock_273326141

Gilead scoops up Immunomedics in deal worth $21 billion

September 14, 2020
Sales and Marketing Gilead, Immunomedics, acquisition, pharma

The Board of Directors from both companies have unanimously agreed for Gilead to acquire Immunomedics for $88 per share in …

News
shutterstock_138095450

Gilead and Jounce Therapeutics forge immuno-oncology partnership worth a potential $700m+

September 2, 2020
Research and Development, Sales and Marketing Gilead, jounce, oncology, pharma

Gilead and Jounce Therapeutics have come together in a new immuno-oncology partnership potentially worth over $700 million. The primary drive …

News
remsss

Gilead says FDA could expand eligibility of coronavirus patients for remdesivir

August 24, 2020
Sales and Marketing FDA, Gilead

The FDA could expand its Emergency Use Authorization (EUA) for Gilead’s remdesivir for treating coronavirus patients, according to Gilead.

News
gilead-sciences

FDA turns down Gilead’s JAK inhibitor filgotinib in rheumatoid arthritis, endangering 2020 approval hopes

August 20, 2020
Research and Development, Sales and Marketing FDA, Gilead, filgotinib

Gilead’s JAK inhibitor filgotinib has been unexpectedly knocked back by the FDA as a therapy to treat moderately to severely …

News
shutterstock_158366573

Racial minority groups are not adequately represented in COVID-19 clinical studies, research argues

August 12, 2020
Research and Development COVID-19, Gilead, pharma, remdesivir

New research has warned that minority groups and people of colour are underrepresented in current trials for COVID-19 therapies, despite …

News
fda

Gilead applies for FDA approval to treat coronavirus patients with remdesivir

August 11, 2020
Manufacturing and Production COVID-19, Gilead, coronavirus

Gilead Sciences has asked the FDA to approve its drug remdesivir to treat COVID-19 patients. The drug would go under …

News
fdaoutsideweb

Kite secures FDA approval for second CAR T therapy Tecartus in relapsed or refractory mantle cell lymphoma

July 27, 2020
Sales and Marketing CAR T, CAR-T, FDA, Gilead, kite pharma

Kite Pharma has chalked up another regulatory success for its parent company Gilead with the news that the FDA has …

News
mylan_building

Mylan launches generic version of Gilead’s remdesivir for COVID-19 patients in India

July 20, 2020
Sales and Marketing COVID-19, Gilead, India, Mylan, generic, remdesivir

Mylan has launched its own generic version of Gilead’s remdesivir on the Indian market for the treatment of patients with …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025